Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 127Precursor Cell Lymphoblastic Leukemia-Lymphoma 45Myelodysplastic Syndromes 25Leukemia 25Burkitt Lymphoma 25Leukemia, Biphenotypic, Acute 20Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 14Lymphoma, Mantle-Cell 14Recurrence 13Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 10Myeloproliferative Disorders 9Lymphoma 9Lymphoma, Non-Hodgkin 8Leukemia, Myelomonocytic, Chronic 8Lymphoma, Large B-Cell, Diffuse 7Down Syndrome 6Neoplasm, Residual 5Hodgkin Disease 5Blast Crisis 5Sarcoma, Myeloid 4Lymphoma, T-Cell 4Leukemia, Monocytic, Acute 4Hematologic Neoplasms 4Lymphoma, Follicular 3Leukemia, Myelomonocytic, Juvenile 3Leukemia, Myelomonocytic, Acute 3Leukemia, Myeloid, Accelerated Phase 3Neoplasms 2Multiple Myeloma 2Lymphoma, B-Cell 2

Interventions

Cyclophosphamide 4Prednisone 3Etoposide 3Doxorubicin 3etoposide phosphate 2Vincristine 2Brentuximab Vedotin 2tazemetostat 1prednylidene 1pembrolizumab 1fludarabine 1duvelisib 1deltacortene 1Prednisolone 1Melphalan 1Cytarabine 1Cholecalciferol 1Carmustine 1Azacitidine 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enteropathy-Associated T-Cell Lymphoma × Cytarabine × 1 year × Clear all
NCT06692452 2026-04-01

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡